{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T05:43:39Z","timestamp":1793511819547,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ijrobp.2017.12.277","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T13:14:27Z","timestamp":1514466867000},"page":"1210-1216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck"],"prefix":"10.1016","volume":"100","author":[{"given":"Patrick D.","family":"Maguire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart M.","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2017.12.277_bib1","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/1097-0142(197206)29:6<1450::AID-CNCR2820290605>3.0.CO;2-Q","article-title":"Elective irradiation of subclinical disease in cancers of the head and neck","volume":"29","author":"Fletcher","year":"1972","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib3","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/1097-0142(197702)39:2+<868::AID-CNCR2820390724>3.0.CO;2-N","article-title":"Treatment of the neck in patients with squamous cell carcinoma of the head and neck","volume":"39","author":"Jesse","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1259\/bjr\/40226390","article-title":"The potential for mathematical modelling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapy","volume":"78","author":"Jones","year":"2005","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib5","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.ijrobp.2007.03.025","article-title":"How much radiation is the chemotherapy worth in advanced head and neck cancer?","volume":"68","author":"Kasibhatla","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijrobp.2008.01.052","article-title":"Correction to Kasibhatla et\u00a0al. How much radiation is the chemotherapy worth in advanced head and neck cancer? (Int J Radiat Oncol Biol Phys 2007;68:1491-1495)","volume":"71","author":"Fowler","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"40","author":"Rose","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib8","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199904153401501","article-title":"Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer","volume":"40","author":"Morris","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib9","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2015.63.1671","article-title":"Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: A randomized phase II trial","volume":"34","author":"Magrini","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijrobp.2009.01.060","article-title":"Selective nodal irradiation for head and neck cancer using intensity-modulated radiotherapy: Application of RTOG consensus guidelines in routine clinical practice","volume":"76","author":"Nangia","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.oraloncology.2014.02.009","article-title":"Patterns-of-failure after helical tomotherapy-based chemoradiotherapy for head and neck cancer: Implications for CTV margin, elective modal dose and bilateral parotid sparing","volume":"50","author":"Dandekar","year":"2014","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib13","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0360-3016(03)01576-1","article-title":"Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for stage III and IVa head and neck cancer in the community","volume":"58","author":"Maguire","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib14","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ijrobp.2009.12.046","article-title":"Phase II trial of hyperfractionated IMRT and concurrent weekly cisplatin for stage III and IVa head and neck cancer","volume":"79","author":"Maguire","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.radonc.2013.06.044","article-title":"Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetric analysis and effect on acute toxicity","volume":"109","author":"Nuyts","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.ijrobp.2015.12.002","article-title":"Patterns of recurrence in electively irradiated lymph node regions after definitive accelerated intensity modulated radiation therapy for head and neck squamous cell carcinoma","volume":"94","author":"Van den Bosch","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib17","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.ijrobp.2011.12.016","article-title":"Elective lymph node irradiation with intensity modulated radiotherapy: Is conventional dose fractionation necessary?","volume":"83","author":"Bedi","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1023\/B:QURE.0000021703.47079.46","article-title":"Interpreting differences in quality of life: The FACT-H&N in laryngeal cancer patients","volume":"13","author":"Ringash","year":"2004","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/cncr.22799","article-title":"Interpreting clinically significant changes in patient-reported outcomes","volume":"110","author":"Ringash","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib21","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijrobp.2016.05.026","article-title":"Prognostic value of p16 status on the development of a complete response in involved oropharynx cancer neck nodes after cisplatin-based chemoradiation: A secondary analysis of NRG Oncology RTOG 0129","volume":"96","author":"Galloway","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djn011","article-title":"Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective trial","volume":"100","author":"Fakhry","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl.","key":"10.1016\/j.ijrobp.2017.12.277_bib23","doi-asserted-by":"crossref","first-page":"LBA6006","DOI":"10.1200\/jco.2014.32.18_suppl.lba6006","article-title":"E1308: Reduced-dose IMRT in human\u00a0papillomavirus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC)","volume":"32","author":"Cmelak","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2015.08.033","article-title":"Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma","volume":"93","author":"Chera","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.12.277_bib25","unstructured":"NRG Oncology. NRG-HN002: A randomized phase II trial for patients with p16 positive, non-smoking associated, locoregionally advanced oropharyngeal cancer. NCT02254278."}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617345030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617345030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T21:50:00Z","timestamp":1535147400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301617345030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0360301617345030"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.12.277","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.12.277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}